Call for Abstracts

for 

The 9th Annual UCHMC Research Symposium

October 10th and October 11th, 2024

UC San Francisco

 San Francisco, California 

Deadline to Submit is September 20th, 2024

The UCHMC Steering Committee seeks original abstracts that address scientific questions, demonstrate new research/developments or contain original scientific results in the area of hematologic malignancies performed by members of University of California institutions and their affiliates. 


Selected Abstracts will be presented at the UCHMC Research Symposium on Friday October 11th, 2024.  Travel and lodging will be provided for oral abstract presenters. 

Responsibilities of the Presenting Author

  • The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the "Contact Information" section of the online abstract submission system.

  • The presenting author must be one of the co-authors listed on the submitted abstract.

  • The presenting author is responsible for the following: 

    • Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.

    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.

    • Obtaining all of the conflict-of-interest disclosure information from co-authors.

    • Forwarding all correspondence to all co-authors

Authors' Consent and Waiver of Claims

  • Each abstract author agrees and certifies that he or she: 

    • has read all of the rules and agrees to be bound by them,

    • is responsible for submission of the abstract in accordance with the rules, and

General Guidelines

  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

  • All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

  • Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please use the "Updated Analyses" section of the abstract form to explain the significance of the new data. The reviewers will have this information available during their evaluation.

  • Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.

  • No revisions can be made after the abstract submission deadline.

  • The presentation at the meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the meeting must match the submitted abstract, although updates on results may be added.

  • Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.

  • It is assumed that the presenting author will have adequate command of English to present and to respond to questions.

Presentation Format

  • All Abstracts submitted will be considered for poster presentation.

  • Abstracts deemed exceptional in original review will be passed on to the UCHMC Steering Committee for further consideration for an oral presentation that would be part of an invited session.

Abstract Review and Selection Process

  • After the submission deadline, all completed and eligible abstracts will be made available to the UCHMC reviewers for blinded review and scoring, and final decisions will be made by the UCHMC Steering Committee by September 27, 2024.

  • Abstracts will be evaluated and scored solely on their scientific merits.

  • Incomplete abstracts will not be reviewed

  • The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.

  • All abstracts submitted will be considered eligible for poster presentation. Poster Sessions allow the viewing of a poster illustration of the abstract. Authors are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for poster presentations. 

Acceptance/Rejection Notification

  • Notification regarding acceptance or rejection of abstracts will be sent to the presenting author by September 30, 2024 by e-mail; consequently, an accurate e-mail address is critical. If your abstract is accepted, the e-mail will specify whether it is accepted as poster or oral presentation. Rejection notifications will also be sent at that time.

Abstract Submission Policies

Conflict-of-Interest Disclosure Policy

  • The UCHMC is committed to ensuring the integrity of its scientific, educational, and research programs. The University of California Conflict-of-Interest Policy requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict.

  • This policy is not intended to prevent a presentation; it is merely intended to openly identify potential conflicts so that audience members may form their own judgments about the presentation with a full disclosure of the facts.

Author Responsibility Regarding Conflict-of-Interest Disclosure

  • The presenting author is responsible for obtaining disclosure information from all co-authors.

  • All authors and co-authors are required to provide any relevant information concerning personal or professional circumstances and relationships that might reasonably be expected to affect the author's view on the presentation.

  • This includes relationships with pharmaceutical companies, biomedical device manufacturers, or other companies whose products or services are related to the subject matter of the presentation topic. If no relevant relationships exist, this must be stated as well.

When to Disclose

Please disclose any relationships or circumstances that might affect or appear to affect the research presented. These relationships include you or any individual with whom you directly share income. Presenting authors of selected abstracts will receive a notification on how to submit their disclosure. 

What to Disclose

You must disclose the relationship and state the name of the company for each of the following areas in which you have maintained a relationship sometime during the past 12 months. Exact dollar amounts are not necessary. You will have the option to note that there is no information to disclose or to provide disclosure information pertinent to the abstract. Disclosed information pertinent to the abstract may include the following areas:

  • Employment

  • Consultancy

  • Ownership interests (including stock options) in a start-up company, the stock of which is not publicly traded

  • Ownership interest (including stock options, but excluding indirect investments through mutual funds and the like) in a publicly traded company

  • Research funding

  • Honoraria directly received from an entity

  • Patents and royalties

  • Paid expert testimony

  • Membership on an entity's board of directors, speakers bureau, or its advisory committees

  • Any other financial relationship

Off-Label Use   

You will be required to note whether your presentation will include discussion of off-label use of products. If so, you must provide a brief explanation.

Other Areas   

During the disclosure submission process, you will also be required to indicate your compliance with the following:

  • If you are providing recommendations involving clinical medicine, these recommendations will be based on evidence that is accepted within the profession of medicine as adequate justification for their indication and contraindications in the care of patients. All scientific research referred to in support of a patient-care recommendation will conform to generally accepted standards of experimental design, data collection, and analysis.

  • The content of the information with which you are involved will promote quality in health care or advances in science and will not promote a specific proprietary or commercial interest. Content for this publication will be well-balanced and unbiased.

  • If you have been trained or utilized by a commercial entity or its agents as a speaker (e.g., participation in a speakers bureau) for any commercial interest, the promotional aspects of that work must not be included in the presentation in any way.

How to Submit an Abstract

All abstracts must be received by September 20, 2024, at 11:59 p.m., Pacific Daylight Time. 

  • Abstracts must be submitted to the UCHMC as a PDF or Word Document via E-mail to JREINER@UCHMC.ORG 

Preparing an Abstract for Submission

Contact Information

  • Your name, degree, institution, address, phone number, and e-mail address must be provided. As the corresponding author, you will receive all future correspondence from the UCHMC

  • The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.

Co-Authors

  • Names of co-authors and institutions must be provided. The program will automatically place an asterisk (*) after the name of each non-member author. Changes will not be made to the spelling of authors' names after the submission deadline; please proof your co-authors' names carefully.

Copyright Policy

  • Authors retain copyright of the abstracts submitted to the UCHMC Research Symposium.

Abstract Title

  • The abstract title should be brief and clearly indicate the nature of the abstract.

  • The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase "to" when used as an infinitive.

  • Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.

  • Do not put a period at the end of the title.

Use of Product Names

  • Non-proprietary (generic/scientific) names should be used and should be lowercase.

  • If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized.

Abbreviations

Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Abstract Body, Tables, and Figures

  • Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract carefully.

  • The entire body of the abstract, including text and tables, must not exceed 3,800 characters. Spaces are not included in this number; title, authors' names, and affiliations are counted separately. Figures are not included in the character count.

  • The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.

  • Do not use bold type or underline formatting. Italic type is acceptable.

  • Text may be in multiple paragraphs.

  • Use numerals to indicate numbers, except when beginning sentences.

  • Simple tables and graphs may be included. 

  • Any references should be noted as citations within the text and not as footnotes at the end.